Clene to Provide CNM-Au8® ALS Program Update

Impact · against what's priced in

Clene provides a specific regulatory milestone by targeting an NDA submission in Q3 2026 via the accelerated approval pathway. This timeline and the upcoming program update serve as near-term catalysts for the stock.

CLNN+0.40

No priced-in read yet

In context

The company has committed to a Q3 2026 timeline for submitting an NDA under the accelerated approval pathway, providing a concrete milestone for the CNM-Au8 ALS program.

Read from the article alone

• pharmaceuticals
• biotech
• CLNN
• als
• clinical trial
• fda
• investor call
• neurodegenerative diseases
• webcast

Search tags